Literature DB >> 8750707

Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the increase in cytosolic Ca2+ concentration.

K Rupalla1, W Cao, J Krieglstein.   

Abstract

We tested the effect of flupirtine against ischemic and excitotoxic neuronal damage as well as on the glutamate-induced rise in cytosolic calcium ion concentration (= [Ca2+]i). For in vivo experiments we used a model of focal cerebral ischemia in mice. The middle cerebral artery was permanently occluded and 48 h afterwards brain tissue was stained with neutral red, perfusion-fixed and the infarct surface was determined planimetrically. Pretreatment with flupirtine significantly reduced the infarct area (controls: 24.3 +/- 4.8 mm2, 1 mg/kg flupirtine: 20.1 +/- 3.6 mm2 and 10 mg/kg flupirtine: 19.5 +/- 3.9 mm2; P < 0.05), whereas postischemic application of flupirtine failed to reduce the infarct area. For in vitro studies, primary neuronal cultures were prepared from the hippocampi of newborn rats and excitotoxic damage was induced by exposing the cells to 500 mu M L-glutamate for 30 min. We could demonstrate that flupirtine (1-10 microM) was capable of protecting neurons against glutamate-induced cytotoxicity. In order to elucidate the underlying mechanism of action, we tested the effect of flupirtine on the glutamate-induced rise in [Ca2+]i using the Ca2+-indicator fura-2. L-Glutamate added in a final concentration of 100 microM to the cultured cells for 16 s caused a rise in [Ca2+]i from about 100 nM to 900 nM. Flupirtine (0.1-10 microM) reduced the glutamate-induced rise in [Ca2+]i concentration dependently.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750707     DOI: 10.1016/0014-2999(95)00570-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.

Authors:  V Pedersen; W J Schmidt
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy.

Authors:  Dayalan Sampath; Robert Valdez; Andrew M White; Yogendra H Raol
Journal:  Neuropharmacology       Date:  2017-06-03       Impact factor: 5.250

3.  Antiparkinsonian effect of flupirtine in monoamine-depleted rats.

Authors:  M Schwarz; M Nolden-Koch; J Purr; G Pergande; F Block
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.

Authors:  Muriel B Sättler; Sarah K Williams; Clemens Neusch; Markus Otto; Jens R Pehlke; Mathias Bähr; Ricarda Diem
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

5.  The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker.

Authors:  Tzu-Rong Su; Wen-Shan Zei; Ching-Chyuan Su; George Hsiao; Min-Jon Lin
Journal:  Evid Based Complement Alternat Med       Date:  2012-03-25       Impact factor: 2.629

6.  Flupirtine: Clinical pharmacology.

Authors:  S Harish; K Bhuvana; Girish M Bengalorkar; Tn Kumar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-04

7.  The indirect NMDAR inhibitor flupirtine induces sustained post-ischemic recovery, neuroprotection and angioneurogenesis.

Authors:  Hanna M Jaeger; Jens R Pehlke; Britta Kaltwasser; Ertugrul Kilic; Mathias Bähr; Dirk M Hermann; Thorsten R Doeppner
Journal:  Oncotarget       Date:  2015-06-10

8.  Role of flupirtine as a preemptive analgesic in patients undergoing laparoscopic cholecystectomy.

Authors:  Ghanshyam Yadav; Shailaja Shankar Behera; Saurabh Kumar Das; Gaurav Jain; Sujali Choupoo; Janak Raj
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Apr-Jun

9.  Effect of flupirtine on the growth and viability of U373 malignant glioma cells.

Authors:  Elango Panchanathan; Gnanasambandan Ramanathan; Bhaskar Venkata Kameswara Subrahmanya Lakkakula
Journal:  Cancer Biol Med       Date:  2013-09       Impact factor: 4.248

10.  Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial.

Authors:  Jan Dörr; Klaus-Dieter Wernecke; Jens Würfel; Judith Bellmann-Strobl; Volker Siffrin; Muriel B Sättler; Mikael Simons; Andreas Linsa; Hayrettin Tumani; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-09       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.